Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 249

1.

[Autoimmune side effects of immune-checkpoint inhibitor therapies in oncology: pathogenesis, clinic and treatment].

Szekanecz É, Szekanecz Z.

Orv Hetil. 2019 Jun;160(23):887-895. doi: 10.1556/650.2019.31392. Hungarian.

PMID:
31155880
2.

Angiogenesis in Inflammatory Arthritis.

Balogh E, Biniecka M, Fearon U, Veale DJ, Szekanecz Z.

Isr Med Assoc J. 2019 May;5(21):345-352. Review.

3.

Remarkable international variability in reasons for ineligibility and non-participation in the GLORIA trial.

Hartman L, Bos R, Buttgereit F, Güler-Yuksel M, Ionescu R, Kok MR, Lems WF, Micaelo M, Opris-Belinski D, Pusztai A, Santos E, Da Silva J, Szekanecz Z, Zeiner K, Zhang D, Boers M.

Scand J Rheumatol. 2019 Jul;48(4):340-341. doi: 10.1080/03009742.2018.1559880. Epub 2019 May 27. No abstract available.

PMID:
31132016
4.

Gene expression analysis of vascular pathophysiology related to anti-TNF treatment in rheumatoid arthritis.

Póliska S, Besenyei T, Végh E, Hamar A, Pusztai A, Váncsa A, Bodnár N, Szamosi S, Csumita M, Kerekes G, Szabó Z, Nagy Z, Szűcs G, Szántó S, Zahuczky G, Nagy L, Szekanecz Z.

Arthritis Res Ther. 2019 Apr 15;21(1):94. doi: 10.1186/s13075-019-1862-6.

5.
6.

Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider.

Unger J, Putrik P, Buttgereit F, Aletaha D, Bianchi G, Bijlsma JWJ, Boonen A, Cikes N, Dias JM, Falzon L, Finckh A, Gossec L, Kvien TK, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Dejaco C, Ramiro S.

RMD Open. 2018 Dec 5;4(2):e000756. doi: 10.1136/rmdopen-2018-000756. eCollection 2018.

7.

EULAR 'points to consider' for the conduction of workforce requirement studies in rheumatology.

Dejaco C, Putrik P, Unger J, Aletaha D, Bianchi G, Bijlsma JW, Boonen A, Cikes N, Finckh A, Gossec L, Kvien TK, Madruga Dias J, Matteson EL, Sivera F, Stamm TA, Szekanecz Z, Wiek D, Zink A, Ramiro S, Buttgereit F.

RMD Open. 2018 Dec 5;4(2):e000780. doi: 10.1136/rmdopen-2018-000780. eCollection 2018.

8.

The NLRP3 inflammasome - interleukin 1 pathway as a therapeutic target in gout.

Szekanecz Z, Szamosi S, Kovács GE, Kocsis E, Benkő S.

Arch Biochem Biophys. 2019 Jan 30. pii: S0003-9861(18)30755-0. doi: 10.1016/j.abb.2019.01.031. [Epub ahead of print] Review.

PMID:
30710503
9.

Peripheral Lymphocyte Multidrug Resistance Activity as a Predictive Tool of Biological Therapeutic Response in Rheumatoid Arthritis.

Toldi G, Batel P, Baráth S, Szerémy P, Apjok A, Filkor K, Szántó S, Szűcs G, Szamosi S, Häupl T, Grützkau A, Szekanecz Z.

J Rheumatol. 2019 Jun;46(6):572-578. doi: 10.3899/jrheum.180793. Epub 2019 Feb 1.

PMID:
30709954
10.

Long-Term Efficacy of Tumor Necrosis Factor Inhibitors for the Treatment of Methotrexate-Naïve Rheumatoid Arthritis: Systematic Literature Review and Meta-Analysis.

Gulácsi L, Zrubka Z, Brodszky V, Rencz F, Alten R, Szekanecz Z, Péntek M.

Adv Ther. 2019 Mar;36(3):721-745. doi: 10.1007/s12325-018-0869-8. Epub 2019 Jan 12.

PMID:
30637590
11.

Common mechanisms and holistic care in atherosclerosis and osteoporosis.

Szekanecz Z, Raterman HG, Pethő Z, Lems WF.

Arthritis Res Ther. 2019 Jan 10;21(1):15. doi: 10.1186/s13075-018-1805-7. Review.

12.

Autoimmune and angiogenic biomarkers in autoimmune atherosclerosis.

Balogh E, Pusztai A, Hamar A, Végh E, Szamosi S, Kerekes G, McCormick J, Biniecka M, Szántó S, Szűcs G, Nagy Z, Fearon U, Veale DJ, Szekanecz Z.

Clin Immunol. 2019 Feb;199:47-51. doi: 10.1016/j.clim.2018.12.011. Epub 2018 Dec 10.

PMID:
30543922
13.

[Recent advances in gout: pathogenesis, diagnosis, comorbidities, treatment].

Soós B, Szamosi S, Benkő S, Paragh G, Szekanecz Z.

Orv Hetil. 2018 Oct;159(40):1625-1636. doi: 10.1556/650.2018.31270. Review. Hungarian.

PMID:
30277413
14.

Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey.

Roodenrijs NMT, de Hair MJH, van der Goes MC, Jacobs JWG, Welsing PMJ, van der Heijde D, Aletaha D, Dougados M, Hyrich KL, McInnes IB, Mueller-Ladner U, Senolt L, Szekanecz Z, van Laar JM, Nagy G; whole EULAR Task Force on development of EULAR recommendations for the comprehensive management of difficult-to-treat rheumatoid arthritis.

Ann Rheum Dis. 2018 Dec;77(12):1705-1709. doi: 10.1136/annrheumdis-2018-213687. Epub 2018 Sep 7.

PMID:
30194273
15.

2018 update of the EULAR recommendations for the management of hand osteoarthritis.

Kloppenburg M, Kroon FP, Blanco FJ, Doherty M, Dziedzic KS, Greibrokk E, Haugen IK, Herrero-Beaumont G, Jonsson H, Kjeken I, Maheu E, Ramonda R, Ritt MJ, Smeets W, Smolen JS, Stamm TA, Szekanecz Z, Wittoek R, Carmona L.

Ann Rheum Dis. 2019 Jan;78(1):16-24. doi: 10.1136/annrheumdis-2018-213826. Epub 2018 Aug 28.

PMID:
30154087
16.

Editorial: Comorbidity Burden in Rheumatic Diseases.

Nikiphorou E, Nurmohamed MT, Szekanecz Z.

Front Med (Lausanne). 2018 Jul 3;5:197. doi: 10.3389/fmed.2018.00197. eCollection 2018. No abstract available.

17.

Corneal Manifestations of Systemic Sclerosis.

Nagy A, Rentka A, Nemeth G, Ziad H, Szücs G, Szekanecz Z, Gesztelyi R, Zsuga J, Aszalos Z, Szodoray P, Kemeny-Beke A.

Ocul Immunol Inflamm. 2018 Jul 17:1-10. doi: 10.1080/09273948.2018.1489556. [Epub ahead of print]

PMID:
30015530
18.

Impact of obesity on autoimmune arthritis and its cardiovascular complications.

Van Raemdonck K, Umar S, Szekanecz Z, Zomorrodi RK, Shahrara S.

Autoimmun Rev. 2018 Aug;17(8):821-835. doi: 10.1016/j.autrev.2018.02.007. Epub 2018 Jun 6. Review.

PMID:
29885537
19.

Oxidative stress impairs energy metabolism in primary cells and synovial tissue of patients with rheumatoid arthritis.

Balogh E, Veale DJ, McGarry T, Orr C, Szekanecz Z, Ng CT, Fearon U, Biniecka M.

Arthritis Res Ther. 2018 May 29;20(1):95. doi: 10.1186/s13075-018-1592-1.

20.

Microthrombotic renal involvement in an SLE patient with concomitant catastrophic antiphospholipid syndrome: the beneficial effect of rituximab treatment.

Diószegi Á, Tarr T, Nagy-Vincze M, Nánásy-Vass M, Veisz R, Bidiga L, Dezső B, Balla J, Szodoray P, Szekanecz Z, Soltész P.

Lupus. 2018 Aug;27(9):1552-1558. doi: 10.1177/0961203318768890. Epub 2018 Apr 10.

PMID:
29635999
21.

The Impact of Drug Metabolism Gene Polymorphisms on Therapeutic Response and Survival in Diffuse Large B-Cell Lymphoma Patients.

Pál I, Illés Á, Gergely L, Pál T, Radnay Z, Szekanecz Z, Zilahi E, Váróczy L.

Isr Med Assoc J. 2018 Apr;20(4):217-221.

22.

Laser-induced plasma spectroscopy (LIPS): use of a geological tool in assessing bone mineral content.

Andrássy L, Gomez I, Horváth Á, Gulyás K, Pethö Z, Juhász B, Bhattoa HP, Szekanecz Z.

Lasers Med Sci. 2018 Aug;33(6):1225-1236. doi: 10.1007/s10103-018-2462-4. Epub 2018 Feb 17.

PMID:
29453616
23.

Increased frequency of temporal acoustic window failure in rheumatoid arthritis: a manifestation of altered bone metabolism?

Kardos Z, Oláh C, Sepsi M, Sas A, Kostyál L, Bóta T, Bhattoa HP, Hodosi K, Kerekes G, Tamási L, Bereczki D, Szekanecz Z.

Clin Rheumatol. 2018 May;37(5):1183-1188. doi: 10.1007/s10067-018-4003-8. Epub 2018 Jan 30.

PMID:
29383454
24.

Posterior Reversible Encephalopathy Syndrome (PRES) Associated with Thrombotic Thrombocytopenic Purpura in a Systemic Lupus Erythematosus Patient.

Szamosi S, Bodnár N, Brugós B, Hortobágyi T, Méhes G, Szabó Z, Végh E, Horváth Á, Szekanecz Z, Szűcs A, Szűcs G.

Isr Med Assoc J. 2017 Nov;19(11):700-702. No abstract available.

25.

Effect of Fcγ-receptor 3a (FCGR3A) gene polymorphisms on rituximab therapy in Hungarian patients with rheumatoid arthritis.

Pál I, Szamosi S, Hodosi K, Szekanecz Z, Váróczy L.

RMD Open. 2017 Nov 1;3(2):e000485. doi: 10.1136/rmdopen-2017-000485. eCollection 2017.

26.

Targeting Cannabinoid Signaling in the Immune System: "High"-ly Exciting Questions, Possibilities, and Challenges.

Oláh A, Szekanecz Z, Bíró T.

Front Immunol. 2017 Nov 10;8:1487. doi: 10.3389/fimmu.2017.01487. eCollection 2017. Review.

27.

Pneumococcal vaccination in autoimmune rheumatic diseases.

Rákóczi É, Szekanecz Z.

RMD Open. 2017 Sep 14;3(2):e000484. doi: 10.1136/rmdopen-2017-000484. eCollection 2017. Review.

28.

Assessment of intracranial vessels in association with carotid atherosclerosis and brain vascular lesions in rheumatoid arthritis.

Oláh C, Kardos Z, Sepsi M, Sas A, Kostyál L, Bhattoa HP, Hodosi K, Kerekes G, Tamási L, Valikovics A, Bereczki D, Szekanecz Z.

Arthritis Res Ther. 2017 Sep 26;19(1):213. doi: 10.1186/s13075-017-1422-x.

29.

[Why would doctors from Debrecen go abroad? Results of a questionnaire].

Szekanecz Z, Tóth Z, Hamar A, Lánczi L.

Orv Hetil. 2017 Sep;158(37):1458-1468. doi: 10.1556/650.2017.30842. Hungarian.

PMID:
28891705
30.

Association between objective signs and subjective symptoms of dry eye disease in patients with systemic sclerosis.

Rentka A, Nagy A, Harsfalvi J, Szucs G, Szekanecz Z, Gesztelyi R, Szodoray P, Kemeny-Beke A.

Rheumatol Int. 2017 Nov;37(11):1835-1845. doi: 10.1007/s00296-017-3794-2. Epub 2017 Sep 7.

PMID:
28884335
31.

Opportunities and challenges in rheumatology research in Central Europe.

Szekanecz Z, Anic B, Héjj G, Holc I, Hunka A, Kucharz E, Machold K, Mayer M, Pahor A, Puchner R, Rovensky J, Senolt L, Tuchynova A, Vencovsky J, Smolen JS.

Arthritis Res Ther. 2017 Sep 4;19(1):196. doi: 10.1186/s13075-017-1368-z.

32.

[Vitamin D metabolism and osteoporosis in systemic sclerosis].

Szamosi S, Horváth Á, Szekanecz Z, Szűcs G.

Orv Hetil. 2017 Aug;158(32):1252-1258. doi: 10.1556/650.2017.30816. Review. Hungarian.

PMID:
28780880
33.

Antigen-specific immunotherapies in rheumatic diseases.

Pozsgay J, Szekanecz Z, Sármay G.

Nat Rev Rheumatol. 2017 Sep;13(9):525-537. doi: 10.1038/nrrheum.2017.107. Epub 2017 Jul 13. Review.

PMID:
28701761
34.

[Experience with a rheumatoid arthritis biobank: analysis of biological samples and clinical data of 204 patients].

Pál I, Pusztai A, Csomor P, Szekanecz Z.

Orv Hetil. 2017 Feb;158(7):270-277. doi: 10.1556/650.2017.30650. Hungarian.

PMID:
28462625
35.

Determinants of biological drug survival in rheumatoid arthritis: evidence from a Hungarian rheumatology center over 8 years of retrospective data.

Brodszky V, Bíró A, Szekanecz Z, Soós B, Baji P, Rencz F, Tóthfalusi L, Gulácsi L, Péntek M.

Clinicoecon Outcomes Res. 2017 Feb 15;9:139-147. doi: 10.2147/CEOR.S124381. eCollection 2017.

36.

Evaluation of commonly used tear sampling methods and their relevance in subsequent biochemical analysis.

Rentka A, Koroskenyi K, Harsfalvi J, Szekanecz Z, Szucs G, Szodoray P, Kemeny-Beke A.

Ann Clin Biochem. 2017 Sep;54(5):521-529. doi: 10.1177/0004563217695843. Epub 2017 Jun 28. Review.

PMID:
28193107
37.

Effects of targeted therapies on the bone in arthritides.

Szentpétery Á, Horváth Á, Gulyás K, Pethö Z, Bhattoa HP, Szántó S, Szücs G, FitzGerald O, Schett G, Szekanecz Z.

Autoimmun Rev. 2017 Mar;16(3):313-320. doi: 10.1016/j.autrev.2017.01.014. Epub 2017 Jan 31. Review.

PMID:
28159704
38.

TLRs, future potential therapeutic targets for RA.

Elshabrawy HA, Essani AE, Szekanecz Z, Fox DA, Shahrara S.

Autoimmun Rev. 2017 Feb;16(2):103-113. doi: 10.1016/j.autrev.2016.12.003. Epub 2016 Dec 15. Review.

39.

2016 update of the EULAR recommendations for the management of early arthritis.

Combe B, Landewe R, Daien CI, Hua C, Aletaha D, Álvaro-Gracia JM, Bakkers M, Brodin N, Burmester GR, Codreanu C, Conway R, Dougados M, Emery P, Ferraccioli G, Fonseca J, Raza K, Silva-Fernández L, Smolen JS, Skingle D, Szekanecz Z, Kvien TK, van der Helm-van Mil A, van Vollenhoven R.

Ann Rheum Dis. 2017 Jun;76(6):948-959. doi: 10.1136/annrheumdis-2016-210602. Epub 2016 Dec 15.

40.

Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls.

Juhász B, Gulyás K, Horváth Á, Pethő Z, Bhattoa HP, Váncsa A, Szekanecz É, Horváth C, Kocsis J, Horváth Z, Hodosi K, Szántó S, Szűcs G, Szekanecz Z.

Osteoporos Int. 2017 Apr;28(4):1271-1277. doi: 10.1007/s00198-016-3850-x. Epub 2016 Dec 10.

PMID:
27942777
41.

EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update.

Agca R, Heslinga SC, Rollefstad S, Heslinga M, McInnes IB, Peters MJ, Kvien TK, Dougados M, Radner H, Atzeni F, Primdahl J, Södergren A, Wallberg Jonsson S, van Rompay J, Zabalan C, Pedersen TR, Jacobsson L, de Vlam K, Gonzalez-Gay MA, Semb AG, Kitas GD, Smulders YM, Szekanecz Z, Sattar N, Symmons DP, Nurmohamed MT.

Ann Rheum Dis. 2017 Jan;76(1):17-28. doi: 10.1136/annrheumdis-2016-209775. Epub 2016 Oct 3. Review.

PMID:
27697765
42.

Novel clinical and therapeutic aspects in autoimmunity.

Amital H, Watad A, Szekanecz Z.

Immunol Res. 2017 Feb;65(1):168-171. doi: 10.1007/s12026-016-8856-0. No abstract available.

PMID:
27665457
43.

[Physiotherapy of cancer patients].

Gomez I, Szekanecz É, Szekanecz Z, Bender T.

Orv Hetil. 2016 Jul;157(31):1224-31. doi: 10.1556/650.2016.30502. Review. Hungarian.

PMID:
27476518
44.

Development of temporomandibular joint arthritis: The use of animal models.

Ghassemi Nejad S, Kobezda T, Tar I, Szekanecz Z.

Joint Bone Spine. 2017 Mar;84(2):145-151. doi: 10.1016/j.jbspin.2016.05.016. Epub 2016 Jul 21. Review.

PMID:
27450200
45.

[Application of immunomodulatory therapeutic antibodies - a new perspective in oncology].

Szamosi S, Váróczy L, Szekanecz Z.

Orv Hetil. 2016 Jun;157 Suppl 2:9-16. doi: 10.1556/OH.2016.30507. Review. Hungarian.

PMID:
27296505
46.

Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept.

Rákóczi É, Perge B, Végh E, Csomor P, Pusztai A, Szamosi S, Bodnár N, Szántó S, Szücs G, Szekanecz Z.

Joint Bone Spine. 2016 Dec;83(6):675-679. doi: 10.1016/j.jbspin.2015.10.017. Epub 2016 Mar 16.

PMID:
26995488
47.

Autoimmune atherosclerosis in 3D: How it develops, how to diagnose and what to do.

Szekanecz Z, Kerekes G, Végh E, Kardos Z, Baráth Z, Tamási L, Shoenfeld Y.

Autoimmun Rev. 2016 Jul;15(7):756-69. doi: 10.1016/j.autrev.2016.03.014. Epub 2016 Mar 12. Review.

PMID:
26979271
48.

Characterization and Localization of Citrullinated Proteoglycan Aggrecan in Human Articular Cartilage.

Glant TT, Ocsko T, Markovics A, Szekanecz Z, Katz RS, Rauch TA, Mikecz K.

PLoS One. 2016 Mar 4;11(3):e0150784. doi: 10.1371/journal.pone.0150784. eCollection 2016.

49.

Patients' access to biological therapy in chronic inflammatory conditions; per capita GDP does not explain the intercountry differences.

Gulácsi L, Rencz F, Poór G, Szekanecz Z, Brodszky V, Baji P, Péntek M.

Ann Rheum Dis. 2016 May;75(5):942-3. doi: 10.1136/annrheumdis-2015-208741. Epub 2016 Feb 17. No abstract available.

PMID:
26888946
50.

Transmembrane TNF-α Reverse Signaling Inhibits Lipopolysaccharide-Induced Proinflammatory Cytokine Formation in Macrophages by Inducing TGF-β: Therapeutic Implications.

Pallai A, Kiss B, Vereb G, Armaka M, Kollias G, Szekanecz Z, Szondy Z.

J Immunol. 2016 Feb 1;196(3):1146-57. doi: 10.4049/jimmunol.1501573. Epub 2016 Jan 4.

Supplemental Content

Loading ...
Support Center